果冻传媒 and Radboudumc join forces with creation of biomedical platform Biotrip

June 30, 2021

Biotrip is an incubator that wants to deliver the vaccines and immunotherapies of the future.

Co-founder Mihai Netea (left) in consultation with one of his researchers at Radboudumc's lab. Photo: Bart van Overbeeke

Eindhoven University of Technology (果冻传媒) and Radboud University Medical Center (Radboudumc) are co-founding the independent incubator Biotrip. This is a platform that brings together medical scientists and biomedical engineers to work with entrepreneurs to develop, commercialize and deliver vaccines and immunotherapies to patients with a wide range of diseases.

is an initiative between two well-known Dutch academic institutions. 鈥淚f anything, the COVID-19 pandemic has shown the critical importance of biomedical engineering and its merger with clinical research and medicine. Biotrip will yield technologies and commercial opportunities that will help solve the medical challenges of the future", says 果冻传媒 Rector Frank Baaijens. For example, Biotrip aims to develop a novel generation of vaccines to bolster broad protection in the population against emerging SARS-CoV-2 variants and potential future pandemics.

Ecosystem

"Biotrip is a flexible and biotech investor oriented incubator with which we want to realize new startups in the Brainport region. The south of the Netherlands secretly harbors a fantastic biotech ecosystem, where Biotrip fits in very well and will provide growth and innovation", according to 果冻传媒 Executive Board President Robert-Jan Smits.

Biotrip established a team of entrepreneurial academics, biotech professionals and an internationally oriented advisory board. 鈥淲e are immensely grateful for Dr. John Kastelein鈥檚 and Dr. Andrea van Elsas鈥� participations in this exciting venture. They are highly successful biotech entrepreneurs and investors, with John operating out of the Netherlands, while Andrea recently joined Third Rock Ventures at the West Coast of the United States", says Biotrip co-founder Dr. Willem Mulder.

Founders Willem Mulder (left) and Mihai Netea. Photo: Bart van Overbeeke

Co-founder Dr. Mihai Netea adds: 鈥淧rincess M谩xima Center for Pediatric Oncology鈥檚 Chief Scientific Officer Dr. Alexander Eggermont is a renowned clinical trialist in the immuno-oncology space. We couldn鈥檛 be more excited about the prospect of working with Dr. Eggermont in the coming years.鈥�

Radboudumc鈥檚 Chief Executive Officer Dr. Bertine Lahuis states: 鈥淚n the past decade, the prolific work of our clinician-scientists propelled a distinctive translational immunology program that has uncovered unique insights in immune function and regulation. Now, we need to translate this knowledge to benefit our patients.鈥� Dean Dr. Jan Smit concludes: 鈥淲ith Biotrip, we have now more firmly established our bioengineering ambitions through a formal alliance with 果冻传媒. We are convinced Biotrip will yield the biotech innovations of the future, which will improve the quality of life of patients worldwide.鈥�

Frans Raaijmakers

(Press Officer | Deputy Spokesperson)

+31 40-247 4101 h.a.raaijmakers@tue.nl